GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (FRA:99Z) » Definitions » Price-to-Free-Cash-Flow

Modus Therapeutics Holding AB (FRA:99Z) Price-to-Free-Cash-Flow : N/A (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB Price-to-Free-Cash-Flow?

As of today (2024-12-12), Modus Therapeutics Holding AB's share price is €0.117. Modus Therapeutics Holding AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.04. Hence, Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow or its related term are showing as below:

FRA:99Z's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 36.74
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Modus Therapeutics Holding AB's Free Cash Flow per Share for the three months ended in Sep. 2024 was €-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-0.04.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -27.90% per year.

During the past 5 years, Modus Therapeutics Holding AB's highest 3-Year average Free Cash Flow per Share Growth Rate was 20.90% per year. The lowest was -27.90% per year. And the median was -3.50% per year.


Modus Therapeutics Holding AB Price-to-Free-Cash-Flow Historical Data

The historical data trend for Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modus Therapeutics Holding AB Price-to-Free-Cash-Flow Chart

Modus Therapeutics Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Modus Therapeutics Holding AB Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow falls into.



Modus Therapeutics Holding AB Price-to-Free-Cash-Flow Calculation

Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.117/-0.039
=N/A

Modus Therapeutics Holding AB's Share Price of today is €0.117.
Modus Therapeutics Holding AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Modus Therapeutics Holding AB  (FRA:99Z) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Modus Therapeutics Holding AB Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Modus Therapeutics Holding AB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Modus Therapeutics Holding AB Business Description

Traded in Other Exchanges
Address
Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney diseases through its patented polysaccharide sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB Headlines

No Headlines